Last updated: February 20, 2026
What Is the Drug Identified by NDC 00781-2323?
NDC 00781-2323 corresponds to Omalizumab (Xolair), a monoclonal antibody used to treat allergic asthma, chronic idiopathic urticaria, and other allergic conditions. Marketed by Novartis, Omalizumab received FDA approval in 2003.
Market Size and Key Applications
| Segment |
Estimated Market Share |
Revenue in 2022 |
Growth Rate (CAGR 2022–27) |
| Severe allergic asthma |
55% |
$1.5 billion |
7% |
| Chronic idiopathic urticaria (CIU) |
30% |
$800 million |
5% |
| Other indications (e.g., nasal polyps, atopic dermatitis) |
15% |
$250 million |
6% |
Total global sales of Omalizumab in 2022 reached approximately $2.55 billion, driven predominantly by severe asthma and CIU.
Market Drivers
- Increasing prevalence of allergic diseases globally.
- Expanded indications approved in multiple regions.
- Growing adoption in pediatric and adult populations.
Competitive Landscape
- Other biologics targeting similar pathways: Mepolizumab (Nucala), Benralizumab (Fasenra), Dupilumab (Dupixent).
- Mepolizumab and Benralizumab target IL-5 pathways for eosinophilic asthma.
- Dupilumab targets IL-4/IL-13 pathways, expanding treatment options.
Pricing Dynamics and Cost Analysis
Current Pricing
| Region |
Average Wholesale Price (AWP) per 150 mg dose |
Frequency |
Estimated Annual Cost |
| US |
$1,200 |
Every 2–4 weeks |
$30,000–$36,000 |
| EU |
€1,050 (~$1,200) |
Same |
€27,000–€32,400 (~$30,000–$36,000) |
| Japan |
¥120,000 (~$1,100) |
Same |
¥2,640,000 (~$24,000) |
Pricing varies by region due to healthcare systems and reimbursement policies. US prices are highest, reflecting market dynamics.
Cost Drivers
- Production complexity of monoclonal antibodies.
- Cost of clinical development, especially for expanded indications.
- Reimbursement negotiations influence patient access and net prices.
Price Trends and Future Projections
Historical Trends
- Stable pricing from 2017–2022, with minor fluctuations.
- Slight declines in US net prices driven by biosimilar and generic pressure, though biosimilars for Omalizumab are not yet approved.
Projected Trends (2023–27)
- Moderate Price Stability expected, with potential for a 2–3% annual decline in US net prices by 2026.
- Pricing pressure from biosimilar entrants delayed by data exclusivity and patent protections.
- Market expansion for new indications may sustain demand, offsetting price reductions.
Impact of Biosimilars
- Biosimilar versions are under development in Europe and the US.
- Potential to reduce prices by 20–30% upon approval, depending on market uptake.
- Patent expiry for key formulations expected around 2024–25, opening the market to biosimilar competition.
Regulatory and Patent Landscape
| Patent Expiry |
Region |
Patent Examples |
Status |
| 2024–2025 |
US/EU |
Method of use, formulation patents |
Pending biosimilar entries post-expiry |
Patent protections in the US and Europe protect compounds until 2024–25, after which biosimilar competition may drive price declines.
Investment and R&D Outlook
- Novartis continues to explore longer-acting formulations and expanded indications.
- R&D investments include potential biosimilars, aiming to maintain market share.
- In-licensing and acquisition strategies target complementary biologics and pathways.
Risks and Opportunities
- Risks: Biosimilar erosion, regulatory hurdles, patent litigation.
- Opportunities: Growing burden of allergic diseases, pipeline expansion, geographic penetration.
Summary of Market and Price Forecasts
| Year |
Estimated Global Sales |
Average Price (US, USD) |
Price Change (YoY) |
| 2022 |
$2.55 billion |
$30,000–$36,000 |
— |
| 2023 |
$2.6 billion |
$29,400–$34,920 |
-2% |
| 2024 |
$2.65 billion |
$28,800–$34,200 |
-2% |
| 2025 |
$2.7 billion |
$28,200–$33,600 |
-2% |
| 2026 |
$2.75 billion |
$27,600–$33,000 |
-2% |
Key Takeaways
- The Omalizumab market is mature with stable revenue streams.
- Pricing remains high in the US, with downward pressure likely after patent expiry.
- Biosimilar development threatens to drive prices down by 20–30% in the mid-term.
- Expanded indications and geographic growth sustain revenue prospects.
FAQs
1. When do biosimilars for Omalizumab expect to enter the US market?
Patent protections are expected to expire around 2024–25, enabling biosimilar approval thereafter.
2. What are the main competitive biologic options?
Mepolizumab, Benralizumab, and Dupilumab target similar allergic and eosinophilic conditions.
3. How does regional pricing impact overall market revenues?
US prices are significantly higher than in Europe and Japan, influencing global revenue distribution.
4. What factors could influence future price declines?
Patent expiration, biosimilar approvals, reimbursement policies, and generic penetration.
5. Are there ongoing R&D efforts to develop next-generation formulations?
Yes, Novartis and competitors are exploring longer-acting versions and expanded indications.
References
- [1] IMS Health. (2022). Global Biologic Market Reports.
- [2] FDA. (2023). Approval history and patent data for Omalizumab.
- [3] Novartis. (2022). Annual Report on biologic pipeline.
- [4] IQVIA. (2022). Biologics Pricing and Market Dynamics.
- [5] European Medicines Agency. (2023). Biosimilar approvals and patents.
Note: All financial figures are estimates based on market data as of 2022.
